影像组学生物标志物预测非小细胞肺癌免疫检查点抑制剂肺炎
回顾性分析186例初治接受免疫检查点抑制剂(ICI)的非小细胞肺癌(NSCLC)患者,并纳入另一医院52例进行外部验证,构建基于增强CT的影像组学-临床列线图预测ICI治疗前免疫检查点抑制剂肺炎(CIP)概率;联合模型训练、验证和外部验证队列AUC分别为0.935、0.905、0.923,优于仅临床模型和仅影像组学模型。
要点
- 联合模型基于年龄、间质性肺病、基线肺气肿和影像组学标签预测CIP概率。
- 训练、验证和外部验证队列AUC分别为0.935、0.905和0.923。
- 联合模型预测效能优于仅临床模型和仅影像组学模型。
核心结论
- 联合影像组学-临床模型能以较好准确性预测NSCLC患者ICI治疗期间CIP概率,可作为指导临床ICI决策的有效工具。
研究设计与样本
- 回顾性分析685例初治接受ICI的NSCLC患者,最终纳入186例,并纳入另一医院52例进行外部验证;基于增强CT提取和筛选影像组学特征,采用支持向量机分类模型区分CIP,以概率作为影像组学标签,结合筛选的临床参数构建影像组学-临床逻辑回归模型,使用ROC、AUC、校准曲线和决策曲线分析进行模型间比较。
关键影像表现/征象
- 联合模型纳入年龄、间质性肺病、基线肺气肿和影像组学标签。
诊断标准与关键数值
- 联合影像组学-临床模型训练队列AUC为0.935,验证队列AUC为0.905,外部验证队列AUC为0.923。
- 仅临床模型训练、验证和外部验证队列AUC分别为0.829、0.826和0.809。
- 仅影像组学模型训练、验证和外部验证队列AUC分别为0.865、0.847和0.841。
临床应用与阅片要点
- 原文结论认为该联合模型可作为指导临床ICI决策的有效工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of non-small cell lung cancer (NSCLC). However, immune-related adverse events still occur, of which checkpoint inhibitor pneumonitis (CIP) is the most common. We aimed to construct and validate a contrast-enhanced computed tomography-based radiomic nomogram to predict the probability of CIP before ICIs treatment in NSCLC.
MATERIALS AND METHODS: We retrospectively analyzed 685 patients with NSCLC who were initially treated with ICIs. A total of 186 patients were included in our study, and an additional 52 patients from another hospital were considered for external validation. After radiomics feature extraction and selection, we applied a support vector machine classification model to distinguish CIP and used the probability as a radiomics signature. A radiomics-clinical logistic regression model was built using the filtered clinical parameters and a radiomic signature. Receiver operating characteristic, area under the curve (AUC), calibration curve, and decision curve analysis was used for inter-model comparison.
RESULTS: The combined radiomics-clinical model constructed using age, interstitial lung disease, emphysema at baseline, and radiomics signature showed an AUC of 0.935, 0.905, and 0.923 for the training, validation, and external validation cohorts, respectively. Compared with the clinical-only (AUC of 0.829, 0.826, and 0.809) and radiomics-only models (0.865, 0.847, and 0.841), the radiomics-clinical displayed better predictive power.
CONCLUSION: This combined radiomics-clinical model predicted the probability of CIP during ICIs treatment in patients with NSCLC with favorable accuracy and could therefore be used as an effective tool to guide clinical ICIs decisions.
引用
- Du Y, Zhang S, Jia X, et al. Radiomics Biomarkers to Predict Checkpoint Inhibitor Pneumonitis in Non-small Cell Lung Cancer. Acad Radiol. 2024. PMID: 39395887. doi:10.1016/j.acra.2024.09.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。